Enzymes As Targets for Drug Design

Content: 
Front Matter, Page iii
Copyright, Page iv
CONTRIBUTORS, Pages vii-ix
PREFACE, Pages xi-xii
ACKNOWLEDGMENTS, Page xiii
1 - ENZYME INHIBITORS AS DRUGS, Pages 1-4
2 - BIOGENESIS OF PHOSPHATIDYLINOSITOL GLYCOSYL MEMBRANE PROTEINS AND THEIR SIGNIFICANCE, Pages 5-10
3 - STRUCTURE AND CATALYTIC FUNCTION OF ADP-RIBOSE POLYMERASE (ADPRT), A TARGET SITE FOR DRUGS INHIBITING MALIGNANT GROWTH, Pages 11-16
4 - MODULATION OF THE DOPAMINERGIC SYSTEM IN CARDIOVASCULAR THERAPEUTICS, Pages 17-29
5 - ALPHA-METHYLDOPA, Pages 31-44
6 - CONSIDERING RECEPTOR NON-SPECIFICITY AS A FACTOR FOR DEVELOPING EFFECT, TISSUE AND RECEPTOR SPECIFIC AGENTS, Pages 45-57
7 - MECHANISM-BASED ENZYME INHIBITORS AS AN APPROACH TO DRUG DESIGN, Pages 59-83
8 - COFACTOR DEPENDENCY IN THE INHIBITION OF STEROID 5 ALPHA-REDUCTASE, Pages 85-100
9 - HYDROXYLASES AS TARGETS FOR DRUG DESIGN, Pages 101-119
10 - ALPHA-FLUOROMETHYLTYROSINE, ALPHA-FLUOROMETHYLTRYPTOPHAN AND BIOGENIC AMINE SYNTHESIS, Pages 121-137
11 - TYROSINE AND TRYPTOPHAN ANALOGUES AS DUAL ENZYME-ACTIVATED INHIBITORS OF MONOAMINE OXIDASE, Pages 139-156
12 - INHIBITION OF POLYAMINE BIOSYNTHESIS AND FUNCTION AS AN APPROACH TO DRUG DESIGN, Pages 157-183
13 - CONCEPTS FOR DERIVING SPECIFIC INHIBITORS OF POLYAMINE BIOSYNTHESIS–HUMAN LUNG CANCER CELLS AS A MODEL SYSTEM, Pages 185-200
14 - THERAPEUTIC UTILITY OF SELECTED ENZYME-ACTIVATED IRREVERSIBLE INHIBITORS, Pages 201-210
15 - INTRA-BLOOD-BRAIN-BARRIER IgG SYNTHESIS IN HIV, Pages 211-217
16 - PROTEINASES IN THE FIBROSIS OF SYSTEMIC SCLEROSIS, Pages 219-224
17 - THERAPEUTIC OPPORTUNITIES IN EICOSANOID BIOSYNTHESIS, Pages 225-231
18 - MAO AS A TARGET FOR DRUG DESIGN: CLINICAL ISSUES, Pages 233-257
Index, Pages 259-267